Seres Therapeutics (MCRB) Tops Q3 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Seres Therapeutics Reports Third Quarter 2016 Financial Results and Provides Operational Progress Update
November 10, 2016 7:30 AM EST
- Analyses of SER-109 Phase 2 results on track for completion by year
end;
Company intends to discuss proposed future SER-109
clinical development plans with the FDA -
- Pipeline progress with SER-287 and SER-262 Phase 1b study execution;
data
read-outs continue to be expected in 2017 -
- New microbiome patent strengthens the Companys intellectual property estate -
- Conference call at 8:00 a.m. ET today -
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Seres Therapeutics Inc., (NASDAQ:... More
